ALBEMARLE CORP Form 10-O May 10, 2018

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 10-O

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ^x 1934

For Quarterly Period Ended March 31, 2018

"TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12658

ALBEMARLE CORPORATION

(Exact name of registrant as specified in its charter)

VIRGINIA 54-1692118 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.)

4350 CONGRESS STREET, SUITE 700

CHARLOTTE, NORTH CAROLINA

28209

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code - (980) 299-5700

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No " Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer x Accelerated filer

Non-accelerated filer "Smaller reporting company"

Emerging growth company "

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes "No x

Number of shares of common stock, \$.01 par value, outstanding as of April 30, 2018: 110,763,247

Table of Contents

ALBEMARLE CORPORATION INDEX – FORM 10-Q

| | | Page Number(s |
|-----------|--|------------------|
| PART I. | FINANCIAL INFORMATION | |
| Item 1. | Financial Statements (Unaudited) | |
| | Consolidated Statements of Income - Three Months Ended March 31, 2018 and 2017 | <u>3</u> |
| | Consolidated Statements of Comprehensive Income - Three Months Ended March 31, 2018 and 2017 | <u>3</u> 4 |
| | Condensed Consolidated Balance Sheets - March 31, 2018 and December 31, 2017 | <u>5</u> |
| | Consolidated Statements of Changes in Equity - Three Months Ended March 31, 2018 and 2017 | <u>6</u> |
| | Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2018 and 2017 | 7 |
| | Notes to the Condensed Consolidated Financial Statements | 8-23 |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 23-36 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | <u>36</u> |
| Item 4. | Controls and Procedures | <u>36</u> |
| PART II. | OTHER INFORMATION | |
| Item 1. | <u>Legal Proceedings</u> | <u>36</u> |
| Item 1A. | Risk Factors | <u>36</u> |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | <u>37</u> |
| Item 6. | <u>Exhibits</u> | <u>37</u> |
| SIGNATURE | <u>S</u> | <u>38</u> |
| EXHIBITS | | |
| 2 | | |

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1.Financial Statements (Unaudited).
ALBEMARLE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands, Except Per Share Amounts)
(Unaudited)

| | Three Months Ended | |
|---|--------------------|-----------|
| | March 31, | |
| | 2018 | 2017 |
| Net sales | \$821,629 | \$722,063 |
| Cost of goods sold | 516,650 | 467,107 |
| Gross profit | 304,979 | 254,956 |
| Selling, general and administrative expenses | 101,370 | 108,928 |
| Research and development expenses | 20,986 | 24,323 |
| Operating profit | 182,623 | 121,705 |
| Interest and financing expenses | (13,538) | (68,513) |
| Other (expenses) income, net | (30,476 | 265 |
| Income before income taxes and equity in net income of unconsolidated investments | 138,609 | 53,457 |
| Income tax expense | 20,361 | 11,971 |
| Income before equity in net income of unconsolidated investments | 118,248 | 41,486 |
| Equity in net income of unconsolidated investments (net of tax) | 20,677 | 21,171 |
| Net income | 138,925 | 62,657 |
| Net income attributable to noncontrolling interests | (7,165 | (11,444) |
| Net income attributable to Albemarle Corporation | \$131,760 | \$51,213 |
| Basic earnings per share | \$1.19 | \$0.46 |
| Diluted earnings per share | \$1.18 | \$0.45 |
| Weighted-average common shares outstanding – basic | 110,681 | 111,986 |
| Weighted-average common shares outstanding – diluted | 111,867 | 113,289 |
| Cash dividends declared per share of common stock | \$0.335 | \$0.32 |
| See accompanying Notes to the Condensed Consolidated Financial Statements. | | |

3

Table of Contents

CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In Thousands) (Unaudited)

| | Three Months Ended | | | | |
|--|--------------------|-----------|--|--|--|
| | March 31, | | | | |
| | 2018 | 2017 | | | |
| Net income | \$138,925 | \$62,657 | | | |
| Other comprehensive income (loss), net of tax: | | | | | |
| Foreign currency translation | 64,891 | 79,055 | | | |
| Pension and postretirement benefits | 3 | (7) | | | |
| Net investment hedge | (14,421) | (13,685) | | | |
| Interest rate swap | 642 | 529 | | | |
| Total other comprehensive income, net of tax | 51,115 | 65,892 | | | |
| Comprehensive income | 190,040 | 128,549 | | | |
| Comprehensive income attributable to noncontrolling interests | (7,351) | (11,905) | | | |
| Comprehensive income attributable to Albemarle Corporation | \$182,689 | \$116,644 | | | |
| See accompanying Notes to the Condensed Consolidated Financial Statements. | | | | | |

4

Table of Contents

ALBEMARLE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands) (Unaudited)

| | March | December |
|--|-----------|-------------|
| | 31, | 31, |
| | 2018 | 2017 |
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$692,188 | \$1,137,303 |
| Trade accounts receivable, less allowance for doubtful accounts (2018 – \$10,098; 2017 – | | 534,326 |
| \$10,425) | 606,968 | 334,320 |
| Other accounts receivable | 43,410 | 37,937 |
| Inventories | 666,567 | 592,781 |
| Other current assets | 113,763 | 136,064 |
| Assets held for sale | 35,829 | 39,152 |
| Total current assets | 2,158,725 | 2,477,563 |
| Property, plant and equipment, at cost | 4,247,345 | 4,124,335 |
| Less accumulated depreciation and amortization | 1,678,139 | 1,631,025 |
| Net property, plant and equipment | 2,569,206 | 2,493,310 |
| Investments | 524,687 | 534,064 |
| Noncurrent assets held for sale | 151,743 | 139,813 |
| Other assets | 78,619 | 74,164 |
| | | |